143 related articles for article (PubMed ID: 24224649)
1. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.
Inati A; Kahale M; Perrine SP; Chui DH; Taher AT; Koussa S; Abi Nasr T; Abbas HA; Ghalie RG
Br J Haematol; 2014 Feb; 164(3):456-8. PubMed ID: 24224649
[No Abstract] [Full Text] [Related]
2. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.
Fucharoen S; Inati A; Siritanaratku N; Thein SL; Wargin WC; Koussa S; Taher A; Chaneim N; Boosalis M; Berenson R; Perrine SP
Br J Haematol; 2013 May; 161(4):587-93. PubMed ID: 23530969
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.
Patthamalai P; Fuchareon S; Chaneiam N; Ghalie RG; Chui DH; Boosalis MS; Perrine SP
Blood; 2014 Mar; 123(12):1956-7. PubMed ID: 24652964
[No Abstract] [Full Text] [Related]
4. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Kutlar A; Reid ME; Inati A; Taher AT; Abboud MR; El-Beshlawy A; Buchanan GR; Smith H; Ataga KI; Perrine SP; Ghalie RG
Am J Hematol; 2013 Nov; 88(11):E255-60. PubMed ID: 23828223
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic reactivation of fetal haemoglobin.
Olivieri NF; Weatherall DJ
Hum Mol Genet; 1998; 7(10):1655-8. PubMed ID: 9735388
[TBL] [Abstract][Full Text] [Related]
6. Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.
Perrine SP; Castaneda SA; Boosalis MS; White GL; Jones BM; Bohacek R
Ann N Y Acad Sci; 2005; 1054():257-65. PubMed ID: 16339673
[TBL] [Abstract][Full Text] [Related]
7. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients.
Rigano P; Pecoraro A; Calzolari R; Troia A; Acuto S; Renda D; Pantalone GR; Maggio A; Di Marzo R
Br J Haematol; 2010 Dec; 151(5):509-15. PubMed ID: 20955403
[TBL] [Abstract][Full Text] [Related]
8. Foetal haemoglobin inducers and thalassaemia: novel achievements.
Gambari R
Blood Transfus; 2010 Jan; 8(1):5-7. PubMed ID: 20104272
[No Abstract] [Full Text] [Related]
9. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia.
Biswas S; Nag A; Ghosh K; Ray R; Roy K; Bandyopadhyay A; Bhattacharyya M
Ann Hematol; 2019 Feb; 98(2):289-299. PubMed ID: 30413899
[TBL] [Abstract][Full Text] [Related]
11. A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia.
Yasara N; Wickramarathne N; Mettananda C; Silva I; Hameed N; Attanayaka K; Rodrigo R; Wickramasinghe N; Perera L; Manamperi A; Premawardhena A; Mettananda S
Sci Rep; 2022 Feb; 12(1):2752. PubMed ID: 35177777
[TBL] [Abstract][Full Text] [Related]
12. Reversing ontogeny.
Bunn HF
N Engl J Med; 1993 Jan; 328(2):129-31. PubMed ID: 7677964
[No Abstract] [Full Text] [Related]
13. Compound heterozygous beta thalassaemia and hereditary persistence of foetal haemoglobin presenting as thalassemia intermedia.
Warushahennadi R; Gamage C; Ananda R; Nirangan K
Indian J Pathol Microbiol; 2023; 66(4):888-890. PubMed ID: 38084559
[No Abstract] [Full Text] [Related]
14. The role of heterocellular hereditary persistence of fetal haemoglobin in beta(0)-thalassaemia intermedia.
Chang YP; Littera R; Garau R; Smith KD; Dover GJ; Iannelli S; Cacace E; Contu L
Br J Haematol; 2001 Sep; 114(4):899-906. PubMed ID: 11564083
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Reid ME; El Beshlawy A; Inati A; Kutlar A; Abboud MR; Haynes J; Ward R; Sharon B; Taher AT; Smith W; Manwani D; Ghalie RG
Am J Hematol; 2014 Jul; 89(7):709-13. PubMed ID: 24677033
[TBL] [Abstract][Full Text] [Related]
16. High-level induction of fetal haemoglobin by pomalidomide in β-thalassaemia/HbE erythroid progenitor cells.
Khamphikham P; Nualkaew T; Pongpaksupasin P; Kaewsakulthong W; Songdej D; Paiboonsukwong K; Engel JD; Hongeng S; Fucharoen S; Sripichai O; Jearawiriyapaisarn N
Br J Haematol; 2020 Jun; 189(6):e240-e245. PubMed ID: 32358840
[No Abstract] [Full Text] [Related]
17. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia.
Saxon BR; Rees D; Olivieri NF
Br J Haematol; 1998 Jun; 101(3):416-9. PubMed ID: 9633880
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of fetal hemoglobin in patients with beta-thalassemia.
Olivieri NF
Semin Hematol; 1996 Jan; 33(1):24-42. PubMed ID: 8714583
[No Abstract] [Full Text] [Related]
19. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
Kutlar A; Ataga K; Reid M; Vichinsky EP; Neumayr L; Blair-Britt L; Labotka R; Glass J; Keefer JR; Wargin WA; Berenson R; Perrine SP
Am J Hematol; 2012 Nov; 87(11):1017-21. PubMed ID: 22887019
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide induces haematologic responses in patients with β-thalassaemia.
Chen J; Zhu W; Cai N; Bu S; Li J; Huang L
Eur J Haematol; 2017 Nov; 99(5):437-441. PubMed ID: 28850716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
